Retrospective pricing adjustments for 9 products
NHS Business Services Authority (NHSBSA) has confirmed that the following 9 products will be granted upward retrospective pricing adjustments because the manufacturer did not update their product NHS list prices on the NHS dictionary of medicines and devices (dm+d) when the new list price changes took effect in 2026.
Following checks carried out by Community Pharmacy England’s Dispensing and Supply team, we asked NHSBSA to investigate and rectify any prescription payments for the period in which list prices were incorrect on dm+d. The table below outlines the price adjustments for the affected products:
| Product | Actual list price | Incorrect list price | Price adjustment | Adjusted for prescriptions dispensed between |
| Aveeno® cream (Kenvue UK Ltd) 100 ml | £4.81 | £4.25 | £0.56 | April to August 2026 |
| Aveeno® cream (Kenvue UK Ltd) 300 ml | £8.74 | £8.56 | £0.18 | April to August 2026 |
| Aveeno® cream (Kenvue UK Ltd) 500 ml | £7.87 | £7.59 | £0.28 | April to August 2026 |
| metaX® low protein lemon wafers (metaX Institut fuer Diaetetik GmbH) 100 gram | £5.85 | £5.65 | £0.20 | August 2026 |
| XPhe® minis tablets (metaX Institut fuer Diaetetik GmbH) 720 tablet 30 x 24 tablets | £177.00 | £170.35 | £6.65 | August 2026 |
| Pro D3® 30,000unit capsules (Synergy Biologics Ltd) 10 capsule | £24.99 | £12.00 | £12.99 | August 2026 |
| K.Yo® semi-solid food 100g pots berry (Vitaflo International Ltd) 4 pot | £38.81 | £37.16 | £1.65 | October 2026 |
| K.Yo® semi-solid food 100g pots berry (Vitaflo International Ltd) 36 pot | £262.04 | £250.88 | £11.16 | October 2026 |
| PKU express plus15® powder 25g sachets raspberry (Vitaflo International Ltd) 30 sachet | £323.52 | £309.74 | £13.78 | October 2026 |
NHSBSA is in the process of re-pricing generic and branded prescriptions (EPS and paper) for the affected products and will apply any upward price adjustments to payments received by affected contractors. NHSBSA will write to advise affected pharmacy owners of any adjustments and in which payment schedules these will appear.
Product and/or pricing information held on dm+d is used to inform the reimbursement arrangements of several products dispensed against NHS prescriptions. Community pharmacy owners should not be faced with dispensing at a loss products supplied against NHS prescriptions because of failures by suppliers to update dm+d in a timely manner. The NHSBSA is reliant on suppliers providing accurate and timely information to support the effective maintenance of dm+d. Community Pharmacy England continues to urge the Department and the NHSBSA to introduce processes to improve the accuracy and quality of product and pricing information held on dm+d and strengthen the requirements for all suppliers to maintain their dm+d product listings.
